Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease

被引:48
作者
Filali, Mohammed [1 ,2 ]
Lalonde, Robert [3 ]
Rivest, Serge [1 ,2 ]
机构
[1] Univ Laval, CHUQ Res Ctr, Lab Endocrinol & Genom, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Dept Mol Med, Quebec City, PQ G1V 4G2, Canada
[3] Univ Rouen, Fac Sci, Dept Psychol, F-76821 Mont St Aignan, France
基金
加拿大健康研究院;
关键词
Alzheimer's disease; Memantine; Transgenic mice; Learning and memory; T-water maze; Nesting behavior; Exploratory activity; Anxiety; DOUBLE TRANSGENIC MICE; NMDA RECEPTOR ANTAGONIST; LONG-TERM POTENTIATION; AMYLOID-BETA; TG2576; MICE; BEHAVIORAL DISINHIBITION; COST-EFFECTIVENESS; RANDOMIZED-TRIAL; DOUBLE-BLIND; ADULT RATS;
D O I
10.1016/j.neuropharm.2011.01.035
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Glutamate neurotoxicity has been proposed to be involved in Alzheimer pathogenesis, with clinical data supporting succesful treatment with the NMDA receptor antagonist memantine. In the present study, the effects of subchronic memantine administration were assessed on spatial and non-spatial learning as well as exploratory activity and nest-building in APP/PS1 mutant mice. Memantine (10 mg/kg, i.p.) was better than placebo during the reversal phase of left-right discrimination, though equivalent to saline for Morris water maze and passive avoidance learning. The drug had no effect on non-learned behaviors in elevated plus-maze exploration and nest-building. These results support a specific action of the NMDA receptor antagonist on behavioral flexibility in mutant mice with amyloid pathology. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:930 / 936
页数:7
相关论文
共 70 条
[1]   Memantine Lowers Amyloid-β Peptide Levels in Neuronal Cultures and in APP/PS1 Transgenic Mice [J].
Alley, George M. ;
Bailey, Jason A. ;
Chen, DeMao ;
Ran, Balmiki ;
Puli, Lakshman K. ;
Tanila, Heikki ;
Banerjee, Pradeep K. ;
Lahiri, Debomoy K. .
JOURNAL OF NEUROSCIENCE RESEARCH, 2010, 88 (01) :143-154
[2]   Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain [J].
Antonanzas F. ;
Rive B. ;
Badenas J.M. ;
Gomez-Lus S. ;
Guilhaume C. .
The European Journal of Health Economics, 2006, 7 (2) :137-144
[3]   EFFECTS OF MEMANTINE ON SOLUBLE Aβ25-35-INDUCED CHANGES IN PEPTIDERGIC AND GLIAL CELLS IN ALZHEIMER'S DISEASE MODEL RAT BRAIN REGIONS [J].
Arif, M. ;
Chikuma, T. ;
Ahmed, Md. M. ;
Nakazato, M. ;
Smith, M. A. ;
Kato, T. .
NEUROSCIENCE, 2009, 164 (03) :1199-1209
[4]  
Bakchine S, 2008, J ALZHEIMERS DIS, V13, P97
[5]   Management of Neuropsychiatric Symptoms in People with Dementia [J].
Ballard, Clive ;
Corbett, Anne .
CNS DRUGS, 2010, 24 (09) :729-739
[6]   Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins [J].
Borchelt, DR ;
Ratovitski, T ;
vanLare, J ;
Lee, MK ;
Gonzales, V ;
Jenkins, NA ;
Copeland, NG ;
Price, DL ;
Sisodia, SS .
NEURON, 1997, 19 (04) :939-945
[7]   Memantine Prevents Sensitivity to Excitotoxic Cell Death of Rat Cortical Neurons Expressing Human Truncated Tau Protein [J].
Cente, Martin ;
Mandakova, Stanislava ;
Filipcik, Peter .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 2009, 29 (6-7) :945-949
[8]   Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation [J].
Chen, HSV ;
Wang, YF ;
Rayudu, PV ;
Edgecomb, P ;
Neill, JC ;
Segal, MM ;
Lipton, SA ;
Jensen, FE .
NEUROSCIENCE, 1998, 86 (04) :1121-1132
[9]   Memantine in the treatment of mild-to-moderate Alzheimer's disease [J].
Cosman, Kelly M. ;
Boyle, Llsa L. ;
Porsteinsson, Anton P. .
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (02) :203-214
[10]   Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test [J].
Costa, Alberto C. S. ;
Scott-McKean, Jonah J. ;
Stasko, Melissa R. .
NEUROPSYCHOPHARMACOLOGY, 2008, 33 (07) :1624-1632